Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness
Autore:
Chou, WH; Yan, FX; de Leon, J; Barnhill, J; Rogers, T; Cronin, M; Pho, M; Xiao, V; Ryder, TB; Liu, WW; Teiling, C; Wedlund, PJ;
Indirizzi:
Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA Univ Kentucky Lexington KY USA 40536 rmaceut Sci, Lexington, KY 40536 USA Univ Kentucky, Coll Med, Dept Psychiat, Lexington, KY 40536 USA Univ Kentucky Lexington KY USA 40536 pt Psychiat, Lexington, KY 40536 USA Dali Med Coll, Dali, Yunnan Province, Peoples R China Dali Med Coll Dali Yunnan Province Peoples R China ince, Peoples R China Eastern State Hosp, Lexington, KY USA Eastern State Hosp Lexington KY USA astern State Hosp, Lexington, KY USA Affymetrix Inc, Santa Clara, CA USA Affymetrix Inc Santa Clara CA USAAffymetrix Inc, Santa Clara, CA USA
Titolo Testata:
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
fascicolo: 2, volume: 20, anno: 2000,
pagine: 246 - 251
SICI:
0271-0749(200004)20:2<246:EOAPSI>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
CYP2D6 GENE DUPLICATION; DRUG-METABOLISM; POOR METABOLIZERS; DEBRISOQUINE; POPULATION; ALLELE; PHENOTYPE; OXIDATION; PHARMACOGENETICS; DESIPRAMINE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Wedlund, PJ Univ Kentucky, Coll Pharm, Div Pharmaceut Sci, Lexington, KY 40536 USA Univ Kentucky Lexington KY USA 40536 Lexington, KY 40536 USA
Citazione:
W.H. Chou et al., "Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness", J CL PSYCH, 20(2), 2000, pp. 246-251

Abstract

The influence of cytochrome P450 2D6 (CYP2D6) genetic variability was examined in psychiatric inpatients by evaluating adverse drug events (ADEs), hospital stays, and total costs over a 1-year period in an extension of at previously published brief report. One hundred consecutive psychiatric patients from Eastern State Hospital in Lexington, Kentucky, were genotyped for CYP2D6 expression. ADEs mere evaluated by a neurologic rating scale, modified Udvalg for Kliniske Undersogelser Side Effect Rating Scale, or chart review. Information on total hospitalization days and total costs mere gatheredfor a 1-year period. Forty-five percent of the patients received medications that were primarily dependent on the CYP2D6 enzyme for their elimination. When the analysis was restricted to just those patients in each group receiving medication heavily dependent on the CYP2D6 enzyme, the following were observed: (1) a trend toward greater numbers of ADEs from medications as one moved from the group with ultrarapid CYP2D6 activity (UM) to the group with absent CYP2D6 activity (PM); (2) the cost of treating patients with extremes in CYP2D6 activity (UM and PM) was on average $4,000 to $6,000 per year greater than the cost of treating patients in the efficient metabolizer(EM) and intermediate metabolizer (IM) groups; and (3) total duration of hospital stay was more pronounced for those in CYP2D6 PIM group. Variance ofhospital stays and costs calculated from these preliminary data suggests that 1,500 to 2,000 patients must be evaluated over at least a 1-year periodto determine whether the CYP2D6 genetic variation significantly alters theduration of hospital stay and costs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 03:25:10